Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Protein Linked to Development of Drug Resistance by Breast Cancer Cells

By LabMedica International staff writers
Posted on 09 Jul 2012
Cancer researchers have found that the protein glucose-regulated protein 78 (GRP78), which is activated in some types of breast tumor cells, may be a key factor in the development of resistance to the primary chemotherapeutic agents tamoxifen and fulvestrant.

Treatment of breast cancer with antiestrogen drugs is designed to induce apoptosis in the more than 70% of breast cancers that express estrogen receptors. More...
However, in many cases, treatment is not effective or - after an initial positive response - the tumor becomes resistant to the drugs.

Investigators at Georgetown University (Washington DC, USA) examined the relationship between GRP78 activation and the development of anti-estrogen resistance by breast cancer cells.

They reported in the July 1, 2012, issue of the journal Cancer Research that tumors with acquired resistance to antiestrogen treatment overexpressed GRP78, while GRP78 overexpression was not observed in cases where the cancer cells were always resistant to the drugs. Knockdown of GRP78 restored antiestrogen sensitivity in resistant cells, and overexpression of GRP78 promoted resistance in sensitive cells.

At the molecular level, GRP78 integrated multiple cellular signaling pathways to inhibit apoptosis and stimulate prosurvival autophagy. GRP78 stimulation of autophagy enabled cancer cells to metabolize misfolded and potentially toxic proteins utilizing a mechanism known as the "unfolded protein response" or UPR.

"Since cancers often grow rapidly, tumors may lack enough energy to properly fold proteins into the correct orientation. These misfolded proteins accumulate in the cell and trigger UPR," said first author Dr. Katherine Cook, an oncology researcher at Georgetown University. "In normal cells UPR is protective, and if the stimuli last for an extended period of time, UPR becomes pro-death. But we have found cancers use the UPR to promote survival. Since GRP78 plays such an important role in drug resistance, it would be of great benefit to develop agents that target this protein."

That GRP78 does not play a role in breast cancers that never responded to antiestrogen therapy suggests that initial resistance and acquired resistance represent separate biological pathways. "This observation is consistent with the emerging concept that acquired resistance may be an adaptive response," said Dr. Cook.

Related Links:

Georgetown University



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.